Viewing nowCombinationSitaplus Tablet 50/850 mg (Sitagliptin, Metformin)
Sitagliptin Hydrochloride Hydrate 56.69mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
CMG Pharmaceutical Co., Ltd.

MFDS item code 202301801 · Approved 2023.06.12 · Insurance code 648604540
Improvement of glycemic control in type 2 diabetes mellitus
This medication is used to assist patients with type 2 diabetes in controlling their blood sugar. By taking this medication alongside meal and exercise therapy, blood sugar can be managed effectively. Sitagliptin and Metformin work together to help lower blood sugar levels. This may also contribute to the prevention of diabetes complications. Proper adjustment according to the patient's health status can lead to even better therapeutic effects.
For antidiabetic therapy, the dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. This medicine is generally taken twice daily with meals. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. The initial dose of this medicine should be determined according to the patient's current treatment regimen. 1. Patients not currently receiving metformin: For patients with no prior history of antidiabetic drug therapy who do not achieve adequate glycemic control with monotherapy, or for whom adequate glycemic control cannot be achieved with sitagliptin monotherapy, the initial dose is 1 tablet of this medicine 50/500 mg twice daily. The dose may be increased to 1 tablet of this medicine 50/1000 mg twice daily. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medicine (see Precautions for Use, 2. Do not administer to the following patients). 2. Patients receiving metformin: - For patients who do not achieve adequate glycemic control with metformin monotherapy, the recommended initial dose of this medicine is sitagliptin 50 mg twice daily (total daily dose 100 mg) plus the current dose of metformin. - Patients switching to this medicine from combination therapy with sitagliptin and metformin may start at their current doses of sitagliptin and metformin. 3. Patients who do not achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial dose of this medicine is sitagliptin 50 mg twice daily (total daily dose 100 mg). The initial dose of metformin should take into account the patient's blood glucose level and current dose. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. When administered in combination with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia induced by the sulfonylurea or insulin (see Precautions for Use, 5. General Precautions). No studies have been conducted to evaluate the safety and efficacy of switching to this medicine in patients previously treated with another oral antihyperglycemic agent. Any change in the treatment regimen for type 2 diabetes may lead to changes in glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate [eGFR] ≥ 45 and < 60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Since the starting dose of metformin is 500 mg or 850 mg once daily, treatment should not be initiated with this medicine. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Do not administer to the following patients).
This medication is composed of two active ingredients, Sitagliptin and Metformin, and is primarily used for the treatment of type 2 diabetes. While taking this medication, severe allergic reactions may occur; therefore, if symptoms such as skin rash or difficulty breathing arise, discontinue use immediately and consult a doctor. Additionally, there is a risk of serious pancreatic inflammation known as pancreatitis; if sudden abdominal pain, nausea, or vomiting occurs, inform medical personnel immediately. Although rare, the Metformin component can cause lethal metabolic acidosis known as lactic acidosis; this medication should not be taken if there is severe dehydration, kidney function impairment, or serious infections. This drug should not be administered to patients with moderate to severe renal impairment, acute heart failure, or acute myocardial infarction, and use should be temporarily suspended before and after tests involving iodine contrast agents. It is advisable not to use this medication in pregnant or nursing women or in children under 18 years of age. During treatment, regular meals and exercise should be maintained for blood glucose control, and regular blood tests and kidney function tests should be performed. Hypoglycemic symptoms may occur, so especially when taken in conjunction with other blood glucose-lowering agents, caution should be exercised for hypoglycemic symptoms. If symptoms occur, sugar should be taken immediately. Alcohol consumption may increase the risk of lactic acidosis; therefore, it is best to avoid drinking while taking this medication. If surgery is imminent or severe infections, trauma, etc., occur, the administration of this medication should be temporarily discontinued and resumed only after the patient's condition stabilizes. This medication contains certain coloring agents; caution should be exercised if allergic reactions to these exist. Finally, if any unusual symptoms or discomfort occur during the use of this medication, it is essential to consult a doctor or pharmacist immediately for appropriate measures.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly sealed container to prevent air or moisture from entering. It is best to maintain the storage temperature between 1 degree and 30 degrees Celsius to preserve the medication's effectiveness for a longer duration.
Pink oval film-coated tablet
Bottle - 100 tablets/bottle, Bottle - 30 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationSitagliptin Hydrochloride Hydrate 56.69mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
CMG Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 113.4mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
GL Pharma Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
GL Pharma Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 113.4mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
GL Pharma Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Korea Hutech Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.